February 24, 2022 | Mitotech CSO to present at Mitochondria-Targeted Drug Development Summit |
January 26, 2022 | Mitotech to Host Key Opinion Leader Webinar on Visomitin®: A Potential Treatment for Dry Eye Disease |
December 15, 2021 | Mitotech granted Orphan Drug Designation by FDA for Visomitin® in LHON |
May 6, 2021 | Mitotech's focus on opthalmology discussed in Fierce Biotech publication |
March 4, 2021 | Mitotech CEO Natalia Perekhvatova to present at OIS Dry Eye Innovation Showcase 2021 |
February 26, 2021 | Mitotech and Essex Bio-Technology announce positive results of VISTA-2 Phase 3 clinical study in Dry Eye Disease |
February 1, 2021 | Mitotech to present at LSX Congress 2021 |
January 11, 2021 | Mitotech S.A. To Present at Biotech Showcase Digital 2021 Conference |
October 23, 2020 | Mitotech to present in Eyecelerator's Retina Livestream organized by AAO and ASCRS |
August 25, 2020 | Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease |
December 12, 2019 | Mitotech and Essex Bio-Technology Announce Enrollment in VISTA-2 - a pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease |
October 29, 2018 | Mitotech Completes First Patient Visit in VISTA-1 - Phase 2b/3 Clinical Study of SkQ1 for Dry Eye Disease |
October 23, 2018 | Mitotech Initiates Phase 2b/3 Clinical Trial of SkQ1 Ophthalmic Solution in Patients with Dry Eye Disease in a Co-Development Effort with Essex Bio-Technology |
July 19, 2018 | Mitotech partners with Essex Bio-Technology for a late-stage clinical program in Dry Eye Disease |
October 24, 2017 | Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action |
April 26, 2017 | Mitotech's SkQ1 improved visual acuity in Leber's Hereditary Optic Neuropathy (LHON) patients |
April 20, 2017 | Mitotech's SkQ1 and its potential for treating age-related disorders discussed in Fierce Biotech publication |
March 21, 2017 | Mitotech's lead compound significantly increased lifespan of rapidly aging mice |
February 10, 2017 | Mitotech discusses SkQ1 and Dry Eye Disease in a recent Fierce Biotech article |
February 7, 2017 | Mitotech will attend the Biotech and Money conference in London, Feb 7-8, 2017 |
January 20, 2017 | Mitotech S.A. Developing a Dry Eye Treatment has been Granted Two U.S. Patents for Pharmaceutical Formulations |
September 9, 2016 | Mitotech S.A. is granted a patent in anti-aging |
July 27, 2016 | Mitotech S.A. announces its Ophthalmic Scientific Advisory Board |
March 20, 2016 | Oxidative stress and dry eye in Review of Ophthalmology |
March 1, 2016 | Mitotech S.A. to present at ARVO 2016 |
February 5, 2016 | Mitotech CEO to present at the annual BIO CEO and Investor Conference 2016 |
January 25, 2016 | Mitotech S.A. to initiate its first clinical study of a systemic formulation of SkQ1 |
January 10, 2016 | Results of SkQ1 U.S. Phase 2 Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal |
December 27, 2015 | Results of Mitotech's Multicenter Clinical Study in Patients with Dry Eye Syndrome published in Advances in Therapy journal |
October 16, 2015 | Mitotech S.A. to present at the 2015 Sofinnova Japan Biopharma Partnering Conference |
May 3, 2015 | Mitotech's posters at ARVO 2015 in Denver, May 3-7 |
April 23, 2015 | Mitotech Announces Phase 2 Data Showing Positive Effect of SkQ1 in Patients with Dry Eye Syndrome |
April 21, 2014 | Mitotech S.A. announces the initiation of Phase II clinical trial in Dry Eye Patients Utilizing the Controlled Adverse Environment |
May 14, 2013 | Mitotech completes series of uveitis studies |
December 9, 2012 | Mitotech's posters at ARVO 2015 in Denver, May 3-7 |
January 17, 2012 | Mitotech initiated pre-clinical program for SkQ1 compound in the U.S. |